dChan - Q Origins Project Archive

PB

>>20018284 Holy Shit! Human Chop Shop discovered in Phoenix AZ. Selling human body parts.

I'm pretty certain I don't want to go on this dig but…trust the science

Biological Resource Center address

E University Dr Phoenix

No Universities on the road in Phoenix

In between University of Arizona and

Arizona State University

aka Glownigger U

Michael Crow In-Q-Tel is President

Mascot: Devils

Right near the airport.

Air National Guard base

Owner of BRC is namedGore

East University Dr is West of West University Drive?? Then there's another East Uni Drive to the East of West Uni Dr….Odd

A former 'body broker' has a surprising theory for why FBI agents found a person's head sewn onto a different torso in an Arizona body-donation center

Warning: This story contains graphic details.

A 2014 FBI raid of a for-profit body-donation center in Phoenix, Arizona, found a woman's head sewn onto a larger man's torso, among other gruesome discoveries.

It's not clear why someone at the centre did it, but Philip Guyett, a former "body broker," offered a surprising theory.

Body-donation centers, like that in Phoenix, often take dead bodies from relatives in exchange for the person's ashes. The center then extracts body parts from the cadaver, and sells them to third parties.

The Arizona center might have sewed another person's head-on in order to make up a full human body to amass enough bones to cremate for their families, Guyett told Business Insider.

A former "body broker" has a surprising theory for why the FBI found different body parts sewn together in a 2014 raid, the gruesome details of which were revealed in court documents in July.

During the raid of the Biological Resource Center (BRC) in Phoenix, Arizona, FBI agents found a woman's head sewn onto a larger male torso — like "Frankenstein" — and hung on a wall, among other gruesome discoveries, according to court documents reported by the Arizona Republic and the local KTVK news station.

Stephen Gore, the Biological Resource Center's owner,pleaded guilty in 2015 to operating an illegal enterprise and was sentenced to one year deferred prison time and four years probation.

It remains unclear why the now-shuttered center sewed the different body parts together. But Philip Guyett, a former "body broker" — who for six years collected dead bodies from funeral homes, recovered body parts for transplant, and sold them to third parties — offered a surprising theory.

Many families who can't afford to cremate their relatives donate various body parts to body-donation centers — like the one Guyett ran, or BRC — in exchange for their cremation and the subsequent return of the ashes.

>>20018819

>I'm pretty certain I don't want to go on this dig but…trust the science

was sentenced to one year deferred prison time and four years probation.

The only body parts that turn into ash are a person's bones. So the Arizona center might have taken away too many of a dead person's bones, and was trying to sew together different people's parts to make up a full body's worth of ashes, Guyett told Business Insider.

Here's his theory:

"If I knew that a family wanted their ashes back, I'd be doing limited recovery [of internal organs or tissues] so that they would get 90% of that bone ash back.

"[But] these other people, they take everything. They'll take the arms, the shoulders, the spine, the hip, and basically all the family would be left with is maybe a cup's worth of ashes from a leftover rib cage or something.

"So I think the family wanted the ashes back, and [the Biological Resource Center] took some body parts that they didn't have to get back, just to make up the volume.

"That would be my assumption because there's no other reason to go through that work of trying to put the body parts back together again."

"It's not normal," he added.

Guyett told Business Insider that his business was entirely legal, and that relatives had explicitly given permission for him to take parts of their loved ones' bodies for research.

His clients included private universities and researchers that needed specific body parts for their teaching exercises. They would require various body parts — from brains to skin grafts to various tissues — to test out new medical technologies, and carry out research of the human body for science.

While his business as a whole was legal, in 2009 Guyett was sentenced to eight years in federal prison for falsifying the medical records of some cadavers that he wanted to sell for transplant.

He served six-and-a-half years, during which time he wrote a book about his experiences — titled "Head Shoulders Knees & Bone$."

"I don't regret being in the business," Guyett, who now works as a land surveyor in Southern California, told Business Insider. "I regret some of the things I did, obviously, but the business was interesting. And I think life should be interesting."

Single cadavers are generally used for several purposes

One cadaver is typically cut up into various body parts, which would then be sold onto a range of buyers — including the US Army.

One man in Arizona is currently suing BRC after finding out that his mother's body, which he donated in hopes that it could be sent for Alzheimer's research,had been sold to the US Armyto test the effects of roadside bombs on troops.

The Army said when the case was first reported that it was unaware the family had not given consent for such testing.

>https://www.businessinsider.com/philip-guyett-body-broker-theory-arizona-center-sewed-body-parts-2019-8

>Google Rev iew

Question about Biological Resource Center Inc

C Brown

4 years ago

Why were you guys sowing body parts together like Leatherface from The Texas Chainsaw Massacre?

TK

4 years ago

things get oh so boring here. you have to pass the time somehow.

>>20018819

>>20018837

>,had been sold to theUS Army

Located in Cyrex Labratories, LLC

Biological Resource Center Inc

1.157 Google reviews

Laboratory in Phoenix, Arizona

Directions

Call

Located in: Cyrex Laboratories LLC

Address: 2602 S 24th St #101, Phoenix, AZ 85034

Hours: Open 24 hours

Phone: (602) 494-4272

Suggest an edit · Own this business?

Add missing information

Cyrex Laboratories Home

Cyrex Labs

https://www.cyrexlabs.com

Cyrex™ is a Clinical Immunology LaboratorySpecializing in Functional Immunology and Autoimmunity. Cyrex™ offers multi-tissueantibody testing for the early …

>>20018868

>Located in: Cyrex Laboratories LLC

President - Jean Bellin

Jean Bellin has more than 30 years experience in the biopharmaceutical industry, including sales, marketing, business development, mergers and acquisitions, and general management – both domestic and international. He began his pharmaceutical industry career with 12 years at Eli Lilly & Company, holding positions in sales, marketing and general management in Brazil, the US, the Scandinavian countries and Italy. He then founded and served as Managing Director of DuPont Pharma Italy. In 1993, Mr. Bellin became the head of the international Pharmaceutical division of UCB, then a $2 billion publicly traded, biopharmaceutical and chemical group based in Brussels, Belgium.There he managed the pharmaceutical subsidiaries inthe US, Canada, South America, Japan,China and Southeast Asia. Later he managed the Osteohealth and Animal Health global divisions of Luitpold Pharmaceuticals, a wholly-owned company of Sankyo Pharmaceuticals Company Ltd., then the second largest pharmaceutical company in Japan. In 2004 and 2005, he was the CEO of Mountain View Pharmaceuticals Inc., a California-based biopharmaceutical company where the PEGylation of therapeutic proteins was a major focus. In 2006, Jean became the President of Metagenics, a global life sciences company, where Mr. Bellin lead and grew the US and international sales, marketing and manufacturing operations of the company for 4 and a half years. Mr. Bellin left Metagenics in October of 2010 after its acquisition by the Alticor group, the $8.2 billion parent company of Nutrilite, the largest vitamin manufacturer in the world.

Mr. Bellin received his bachelor’s degree in Economic, Political and Social Sciences from the Facultés Universitaires Saint Louis in Brussels and a License in Applied Economic Sciences from the Université Catholique de Louvain in Belgium.

>>20018902

>>Located in: Cyrex Laboratories LLC

>President - Jean Bellin

Same Guy?

Actors

son

>His father said he never doubted Seb would pull through.

I bet

Check out the duping delight on his wife: "Extremely Terrifying"

CBS Evening News

'''Basketball player wounded in Brussels bombings reunites with family

evening-news'''

By Vladimir Duthiers

March 30, 2016 / 7:21 PM EDT / CBS News

BRUSSELS –Police have discovered that the terrorists who bombed Brusselshad pictures of the Belgian prime minister's residence and office on a laptop.

More than 30 people were killed in the attacks. Nearly 90 are still in the hospital, including Sebastien Bellin, who played college basketball in the United States.

It was a surprise reunion like no other. CBS News was there to see Bellin reunited with his father Jean,stepmother Lisa, his wife Sarah and two younger brothers.

"We couldn't wait to see you, Sebby," Jean Bellin told his son.

"This makes it real," Seb responded.

Bellin came close to death eight days ago after terrorist bombs ripped through the Brussels airport, sending the 6'10'' athlete flying more than 50 feet into the air.

He's recovering from four surgeries to his hips and legs.

"Seeing that photo was, I mean, extremely terrifying and to think that that happened to our family and – it's like an invasion into your little circle," Sarah told CBS News.

His father said he never doubted Seb would pull through.

"I think the initial shock of seeing that picture – we both lost it and I was completely in shock for maybe three minutes, but then, you know, I started looking at the picture more closely and said, 'Okay, he's going to be okay."

"This is surreal, I'm so sorry I'm at a loss for words," Seb said. "If you would have told me that this was going to happen a week after lying on the floor in that airport – it's two extremes. I don't know how I'll ever repay my gratitude to have my family around me."

It's not clear how long the recovery process will be, but Seb's family said they'll be with him every step of the way.

A GoFundMe page has been created to raise funds for Sebastien Bellin.

https://www.cbsnews.com/news/brussels-attacks-sebastien-bellin-basketball-player-wounded-in-bombings-reunites-with-family/

>>20018902

>>20018912

Number of Current Board & Advisor Roles

1

Jean Bellin is the Director, Board Member, Audit Committee Chairman and Consultant at Advanced Proteome Therapeutics.

Advanced Proteome Therapeutics Logo

Advanced Proteome Therapeutics

Director, Board Member, Audit Committee Chairman and Consultant

2007

About Us

Overview

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates.Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.

The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies.

https://web.archive.org/web/20070915181750/http://www.advancedproteome.com/about.html

>>20019011

>proteins require enhancements in

Enhancing protein therapeutics

through selective modification

Advanced Proteome Therapeutics is developing a new technology platform that can shorten the time-to-market for the commercialization of protein therapeutics. This patent-pending technology platform incorporates a novel method for the selective modification of proteins that affords opportunities to improve key therapeutic properties. The technology has the potential of improving the properties of a growing list of off-patent protein therapeutics resulting in the development of investigational new drugs. APT’s commercialization strategy is to modify selected protein therapeutics, demonstrate their improved properties though in-vivo testing, and then partner with established pharmaceutical companies.

The Company’s technology features a method of attaching efficacy-enhancing entities to proteins to improve their therapeutic properties. APT’s technology exploits molecular chaperones that are capable of guiding enhancing entities to sites on the protein that are key to improving such properties. A unique, commercially and clinically attractive feature of the technology is that it does not require changing or mutating the protein’s natural sequence since such modifications might induce undesirable immunological reactions.

Advanced Proteome Therapeutics’ technology holds forth the prospect of rapidly generating therapeutic proteins with enhanced properties, in the fastest growing segment of the market for ethical drugs. Of particular interest are commercially viable protein therapeutics with established markets which are candidates for redevelopment that will benefit the patient population and create new patent life.

Our technology platform provides APT with the capability to generate targeted libraries with distinct chemical properties, to screen for entities with the optimal characteristics for each application, and to reproducibly prepare suitable candidates that emerge from the screen for advanced testing. The Company’s technology is applicable not only to protein drugs, but to potentially a broad range of protein products in the fields of diagnostics and proteomics.

>>20019033

>nhancing protein therapeutics

>through selective modification

September 21, 2011

Advanced Proteome Therapeutics Extends Agreement with Major Global Pharmaceutical Company

Advanced Proteome Therapeutics (the “Company” or “APC”) is pleased to announce that it has extended an agreement for a feasibility study with a leading global pharmaceutical company interested in evaluating APT’sproprietary crosslinking technologies, for another year.

Per the agreement, APC will chemically modify a specified entity by site-specifically attaching it to a variety of carriers that are designed to afford improved properties in clinical settings. Key properties of the modified entities are then evaluated. First generation APT prototype linkers have shown promising stability versus established industrial linkers and provide a basis for further improvements by chemical modification. APC has developed several linker technologies and filed multiple patent applications to cover its inventions in the area of protein modification which it believes provide important scientific and commercial advantages and represent State-of- the-Art advances. The agreement involves certain linker types that are proprietary to APT and are relevant to stability issues of interest to pharmaceutical manufacturers.

“Advanced Proteome Therapeutics has applied components of our platform to a specific initiative of a leading global pharmaceutical company, while accelerating our platform’s development and expanding its scope. A strategy has emerged for designing superior linker motifs, the successful implementation of which positions our Company for ongoing collaborations, business agreements and financial support, that should stimulate interest from additional top-tier partners” said Alexander Krantz, President and CEO of APC.

“As well, the Company is targeting ischemic diseases with significant unmet needs and potential billion dollar markets with our proprietary protein conjugate molecules. This is an exciting time for the Company as specific blockbuster therapeutic applications involving regenerative medicine are being pursued intensively.”

The Company also wishes to announce that it will make an application to the TSX Venture Exchange to amend 1,500,000 share purchase warrants by extending the expiry date of the warrants and reducing the exercise price.

The warrants form part of a private placement financing which closed on October 21, 2010 consisting of 3,000,000 units issued at a purchase price of $0.30 per unit, with each unit consisting of one common share and one-half of a share purchase warrant, each whole warrant entitling the holder to purchase one additional common share at a purchase price of $0.50 per share on or before October 20, 2011. No insiders participated in the private placement.

In accordance with TSX Venture policies allowing for the extension and variation of terms of the previously issued share purchase warrants, the Company intends to amend the terms of the warrants by extending the exercise term of the warrants for an additional nine months, from an

expiry date of October 20, 2011 to an expiry date of July 20, 2012, and by amending the exercise price of these warrants to $0.30 per share. Pursuant to the policies of the Exchange, the exercise period will be reduced to 30 days if, for any 10 consecutive trading days during the unexpired term of the warrants, the closing price exceeds $0.375.

The amendment is subject to consent from all of the warrant holders to the above amendment, which amendment is subject to approval by the TSX Venture Exchange.

About APC

APC’s primary corporate primary mission is to apply its proprietary drug delivery and drug redevelopment technologies to produce new, improved versions of therapeutic proteins and pioneer the emerging field of protein-site targeting. The market for diagnostics and therapeutic proteins and peptides is expected to surpass more than 50 Billion USD by the year 2010 and is the fastest growing segment of the pharmaceutical market. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and the need for homogeneous conjugates that APC is attempting to address.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz

President and Chief Executive Officer

>>20019039

Advanced Proteome Therapeutics Provides Update on Covid Program

Burnaby, British Columbia / August 24, 2021 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

As previously announced, APTI’s scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and preliminary testing were initiated. In fall of last year, the program was deprioritized in the setting of highly efficacious vaccines entering the market and the promise that the COVID pandemic could be controlled.

As the pandemic continues on andthe reality that SARS-CoV-2 is likely to be an endemic virus with new variants that elude current vaccines arising, APTI is planning to reallocate resources toward the development of SARS-CoV-2 protease inhibitors.The SARS-CoV-2 main protease is expected to be highly conserved as the virus evolves and is therefore an optimal therapeutic target.

APTI has engaged Dr. Michael Angelastro to advise on this project. Dr. Angelastro has spent over 30 years in big pharma at Sanofi and its legacy companies reaching the role of Senior Principal Scientist. Over his career, he synthesized multiple clinical candidates including cysteine and serine protease inhibitors. Cysteine protease inhibitors that he synthesized have been hits on prior screens for the SARS-CoV-2 protease.

The first step in revisiting the program will be confirming our previous hits and running an expanded screen utilizing more powerful modeling software. This will be followed by synthesizing additional compounds and testing activity on the SARS-CoV-2 main protease before proceeding with testing on live virus.

The allocation of resources to this project is being pursued in a manner that it will not have a significant impact on our core antibody-drug conjugate research and development.

Dr. Benjamin Krantz, CEO of APTI, said, “The dynamics of COVID pandemic have made it clear that SARS-CoV-2 variants will be staying with us and in time new variants will arise. Especially in the face of vaccine hesitancy and the potential for diminishing efficacy of vaccines, a therapeutic against a conserved target like the SARS-CoV-2 main protease is in great need. Therefore, now is the appropriate time to rededicate resources to this project. We have already identified hits with our prior modeling efforts, and we are excited to use more powerful tools to further validate our approach. Additionally, the engagement of Dr. Michael Angelastro as an advisor on this project will bring decades of synthetic chemistry expertise in this space and valuable insight into the project.”

Dr. Michael Angelastro commented, “I am excited to be working with Advanced Proteome on this project. The approach that APT is taking has the ability to generate protease inhibitors with significantly improved activity and pharmacokinetics compared to typical small molecule approaches. I plan to apply the lessons learned from my 30 years of experience with the optimization of pharmacological properties to the structures identified by APT computer-aided drug design. The modeling to date has yielded molecules with strong predicted activity and the general approach has potential therapeutic applications beyond the SARSCoV-2 protease. I am looking forward to contributing to the development of a platform which will be able to rapidly deliver analogs of the APT pharmacophore to inhibit protease targets of the future with a focus on viral proteases.”

The Company is not making any express or implied claims that it has the ability to eliminate, cure, or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Anonymous ID: a768d1 Dec. 3, 2023, 7:16 a.m. No.20019076 🗄️.is 🔗kun >>9164

>>20019070

>Advanced Proteome Therapeutics Provides Update on Covid Program

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation

Paul Woodward

President and CEO

Tel: (604)690-3797

https://www.advancedproteome.com

https://web.archive.org/web/20210927044116/https://www.advancedproteome.com/2021/08/24/advanced-proteome-therapeutics-provides-update-on-covid-program/